Icatibant Fresenius

Icatibant, the active ingredient in Icatibant Fresenius, is a bradykinin B2 receptor antagonist presented as a subcutaneous solution for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with a confirmed diagnosis and helps to rapidly reduce swelling and associated discomfort.

GNH USA supplies Icatibant Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is a targeted therapy for bradykinin‑mediated angioedema conditions, providing rapid symptom relief.

- Acute hereditary angioedema attacks: reduces swelling and shortens the duration of an episode. - Hereditary angioedema type I: controls episodic edema during attacks. - Hereditary angioedema type II: alleviates swelling when attacks occur.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic response.

Common Side Effects: - Injection site pain: discomfort at the site of administration. - Redness or erythema: localized skin irritation. - Swelling at injection site: mild edema around the needle area. - Nausea: occasional gastrointestinal upset. - Headache: transient cranial discomfort. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, itching, or hives. - Anaphylaxis: severe, potentially life‑threatening allergic response. - Severe hypotension: marked drop in blood pressure requiring medical attention.

Before using Icatibant, clinicians should consider several safety measures to minimize risks.

- Assess patient for known hypersensitivity: avoid use if a prior allergic reaction to icatibant or its excipients has occurred. - Monitor airway after injection: observe for signs of airway obstruction, especially in severe attacks. - Use with caution in renal impairment: adjust monitoring as drug clearance may be affected. - Pregnancy and lactation: safety data are limited; weigh potential benefits against unknown risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medications that influence bradykinin levels or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin concentrations and raise the risk of angioedema. - Concomitant use of other bradykinin B2 antagonists: additive pharmacologic effect could lead to unexpected outcomes.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate swelling or interfere with symptom control. - Estrogen‑containing contraceptives: can increase frequency of hereditary angioedema attacks. - C1‑inhibitor concentrate therapy: no direct interaction, but clinical monitoring is advised when both are used sequentially.